Gland Pharma Ltd (GLAND) — Corporate Action | 13 September 2026 (2 announcements)

Gland Pharma announced the allotment of 42,393 equity shares under ESOP 2025 and 1,800 shares under ESOP 2019 on September 13, 2026, following approval by the ESOP Compensation Committee. The formal closure of ESOP 2019 was also approved as all options were exercised or lapsed. The total issued share capital increased to Rs. 165,010,854, comprising 165,010,854 equity shares of Re.1 each. This action reflects the company's ongoing use of employee stock options and the completion of the 2019 scheme.

Gland Pharma announced on September 13, 2026, that its board approved acquiring 100% of Gland Pharma USA Inc., a US-based wholly-owned subsidiary, for USD 5,01,208 in cash. The transaction, exempt from shareholder approval due to related-party status, will streamline the corporate structure by making Gland US a direct subsidiary. Completion is targeted by October 31, 2026, with no material operational impact.